Core Insights - Incyte Corporation (INCY) is a biopharmaceutical company with a market cap of $20.9 billion, focusing on innovative therapeutics in oncology, immunology, and dermatology [1] Financial Performance - Analysts expect Incyte to report a profit of $1.66 per share for fiscal Q4 2025, representing a 52.3% increase from $1.09 per share in the same quarter last year [2] - For fiscal 2025, EPS is forecasted to be $5.86, a significant increase from $0.08 in fiscal 2024 [3] - Incyte reported Q3 2025 results with adjusted EPS of $2.26 and total revenue of $1.37 billion, marking a 20% year-over-year growth [5] Product Performance - Key product revenues include Jakafi at $791 million, Opzelura at $188 million, and Niktimvo with $46 million in sales [5] - Incyte raised its full-year 2025 net product revenue guidance to between $4.23 billion and $4.32 billion [5] Stock Performance - INCY stock has increased by 50.7% over the past 52 weeks, outperforming the S&P 500 Index's gain of 19.7% and the State Street Health Care Select Sector SPDR ETF's return of 12.7% [4] Analyst Ratings - The consensus rating for INCY stock is "Moderate Buy," with 12 "Strong Buy," 12 "Holds," and one "Strong Sell" among 25 analysts [6] - The current trading price is above the average analyst price target of $102.09 [6]